Company news
Pasithea Therapeutics Corp. news in 2026
Pasithea Therapeutics Corp.'s news releases, calls and decks from 2026, newest first.
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
November 3, 2026
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
October 28, 2026
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
October 23, 2026
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
September 14, 2026
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
September 3, 2026
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
July 21, 2026
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
July 8, 2026
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
June 30, 2026
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
June 16, 2026
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
June 15, 2026
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
June 2, 2026
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
May 4, 2026
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
April 20, 2026
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity
April 2, 2026
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
March 31, 2026
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
January 13, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 20 slides · September 2026